Aequus and Ehave Collaborate on Bioinformatics Platform
Aequus Pharmaceuticals announced it entered a new collaboration with Ehave.
Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) announced it entered a new collaboration with Ehave (OTCQB:EHVVF) whereby Aequus will gain access to Ehave’s bioinformatics platform for use in their upcoming clinical trials for its portfolio products.
As quoted in the press release:
The two companies plan to collaborate on conducting trials in both the traditional pharmaceutical drug regulatory regime and in the medical cannabis regulatory regime. Aequus will pay Ehave a per-patient fee for trials conducted using the Ehave bioinformatics platform and will receive patient assessment, diagnostic and therapeutic outcomes and side-effect profiles content from formal and informal studies conducted using the Ehave platform, subject to standard patient consent and clinical research ethics approvals. Aequus will own all clinical results and data generated from trials using the Ehave platform.
“We are excited to work with Ehave as we advance various development programs, both our traditional pharmaceutical products and medical cannabinoid containing products, through clinical trials,” says Doug Janzen, Chairman and CEO of Aequus.